Moneycontrol PRO
HomeNewsTrendsCurrent AffairsWhy govt recommends increasing interval between the first and second dose of Covishield

Why govt recommends increasing interval between the first and second dose of Covishield

The Centre’s advice to increase the gap between two doses of COVID-19 vaccine from four to six weeks to six to eight weeks, pertains only to Covishield and not Covaxin.

March 22, 2021 / 21:05 IST
Representational image

The Centre, in a written advisory to the chief secretaries of states and administrators of union territories, recommended on March 22 that the interval between two doses of Oxford-AstraZeneca’s COVID-19 vaccine Covishield, be increased.

India’s drug regulator has approved two vaccines for emergency use – Covishield, which is being manufactured by the Serum Institute of India, and Bharat Biotech's Covaxin.

The Centre’s advice to increase the gap between two doses of COVID-19 vaccine from four to six weeks to six to eight weeks, however, pertains only to Covishield and not Covaxin.

Explaining the reason behind the advisory, the central government said that the National Technical Advisory Group on Immunization (NTAGI) and the National Expert Group on Vaccine Administration have advised increasing the current interval period being followed in India citing scientific evidence.

Evidence has emerged showing enhanced protection if the second dose of Covishield is delayed by six weeks and more, but not exceeding the stipulated period of eight weeks.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Besides, Oxford-led clinical trials have confirmed that the Covishield vaccine has 76 percent efficacy three weeks after the first dose that, which increases up to 82 percent if the inter-dose interval is increased to 12 weeks or more.

The study also stated that the COVID-19 vaccine efficacy dipped to only 54.9 percent, if the two doses are given less than six weeks apart.

Follow our coverage of the coronavirus crisis here

Moneycontrol News
first published: Mar 22, 2021 08:40 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347